BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36230522)

  • 1. The Role of Biomarkers in the Management of Colorectal Liver Metastases.
    Hewitt DB; Brown ZJ; Pawlik TM
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Molecular Status on Metastasectomy of Colorectal Cancer Liver Metastases.
    Wang YY; Xin ZC; Wang K
    Clin Colon Rectal Surg; 2023 Nov; 36(6):423-429. PubMed ID: 37795466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Biopsy by ctDNA in Liver Transplantation for Colorectal Cancer Liver Metastasis.
    Wehrle CJ; Raj R; Aykun N; Orabi D; Estfan B; Kamath S; Krishnamurthi S; Fujiki M; Hashimoto K; Quintini C; Kwon DCH; Diago-Uso T; Sasaki K; Aucejo FN
    J Gastrointest Surg; 2023 Jul; 27(7):1498-1509. PubMed ID: 37273078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis].
    Bao Q; Wang K; Wang HW; Jin KM; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):976-983. PubMed ID: 33053993
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary Tumor Sidedness, RAS and BRAF Mutations and MSI Status as Prognostic Factors in Patients with Colorectal Liver Metastases Treated with Surgery and Thermal Ablation: Results from the Amsterdam Colorectal Liver Met Registry (AmCORE).
    Dijkstra M; Nieuwenhuizen S; Puijk RS; Timmer FEF; Geboers B; Schouten EAC; Opperman J; Scheffer HJ; de Vries JJJ; Versteeg KS; Lissenberg-Witte BI; van den Tol MP; Meijerink MR
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies.
    Kitsel Y; Cooke T; Sotirchos V; Sofocleous CT
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
    Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
    Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.
    Schwarz RE; Berlin JD; Lenz HJ; Nordlinger B; Rubbia-Brandt L; Choti MA
    HPB (Oxford); 2013 Feb; 15(2):106-15. PubMed ID: 23297721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.
    Kobayashi S; Takahashi S; Nomura S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N; Taniguchi H; Yoshino T
    Cancer Med; 2021 Oct; 10(20):6998-7011. PubMed ID: 34535965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized treatment in patients with colorectal liver metastases.
    Moris D; Pawlik TM
    J Surg Res; 2017 Aug; 216():26-29. PubMed ID: 28807210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases.
    Rhaiem R; Rached L; Tashkandi A; Bouché O; Kianmanesh R
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
    Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M
    BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases.
    Kobayashi S; Nakamura Y; Taniguchi H; Odegaard JI; Nomura S; Kojima M; Sugimoto M; Konishi M; Gotohda N; Takahashi S; Yoshino T
    Ann Surg Oncol; 2021 Aug; 28(8):4744-4755. PubMed ID: 33393041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
    Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
    Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases.
    Wong GYM; Diakos C; Hugh TJ; Molloy MP
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
    Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
    Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.